10/28/2021
•2021Press Release
Visby Medical Appoints Industry Veteran Thomas Prescott as Chairman of the Board
Thomas Prescott, former president and chief executive officer (CEO) of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board.
![blog_hero_tom_prescott blog_hero_tom_prescott](http://visbywpstaging.visbyon-site.net/wp-content/uploads/elementor/thumbs/blog_hero_tom_prescott-qhtoqaobja1qiyjjp19zyf982xszp5yxmn9omkir88.webp)
SAN JOSE, CA, October 28, 2021 – Visby Medical™, a leading medical diagnostic company, today announced Thomas Prescott, former president and chief executive officer (CEO) of Align Technology and Cardiac Pathways, will join as the company’s new chairman of the board. In his new role, Prescott will lead the Board of Directors and provide strategic counsel on critical growth initiatives for the company.
“I am excited to welcome Tom to the Visby team,” said Visby Medical Founder and CEO Adam de la Zerda. “With decades of experience in multiple leadership positions at innovative medical technology companies, Tom is well-positioned as a very valuable resource for Visby and will help guide our growth. We are very pleased to have him on board.”
Prescott previously served for 13 years as president, CEO and director of Align Technology, a global medical device company and creator of Invisalign, transforming the company from a new public start up to a market leader that established a new category of clear aligner therapy and digital dentistry. He continued to serve as a director of Align until May 2021. Prior to that, he served as president, CEO and director of Cardiac Pathways and held various executive and general management roles at Nellcor Puritan Bennett and GE Medical Systems. Prescott also serves as director and chairman at Earlens Corporation, a board member for The Navy SEAL Foundation, and a trustee at The Naval Postgraduate School Foundation.
“I’m honored to take on this role with an innovative company with proven success delivering the world’s first instrument-free, single-use PCR platform that accurately and rapidly tests for serious infections,” Prescott said. “These advances will be critical in changing the way people are diagnosed and treated for serious infections, and I look forward to working closely with the board to ensure Visby Medical makes a positive impact for all stakeholders.”
Prescott earned his master’s degree from Kellogg Graduate School of Management at Northwestern University and his bachelor’s degree in Civil Engineering from Arizona State University. He is an avid investor, and supports innovation and entrepreneurship at his alma mater, The Fulton School of Engineering at Arizona State University.
About Visby Medical™
Visby Medical is a diagnostics company that is transforming the order of diagnosis and treatment for infectious diseases. The Company’s proprietary technology development program culminated in the world’s first instrument-free, single-use PCR platform that fits in the palm of your hand and rapidly tests for serious infections. Originally developed for sexually transmitted infections, the Company’s FDA-cleared, CLIA-waived Sexual Health Click Test for women returns accurate results within 28 minutes. The Visby Medical technology is also helping to fight the global pandemic via the Visby Medical COVID-19 Test, and its robust pipeline includes tests
Read more articles & insights
CARB-X awards funding to Visby Medical for gonorrhea, antibiotic susceptibility test
The Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) announced today that it will award biotechnology company Visby Medical of San Jose, California, up to $1.8 million to develop a portable polymerase chain reaction (PCR) test that can detect gonorrhea and assess its susceptibility to ciprofloxacin.
Visby Medical™ Receives FDA Clearance and CLIA Waiver for second Generation Sexual Health Test for Women
Visby Medical™ announced today that it has received 510(k) clearance and was granted a CLIA waiver from the FDA for its 2nd generation point of care (POC) test.
Visby Medical Receives FDA Emergency Use Authorization for Respiratory Health Test for Use in CLIA Waived Settings
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.
Visby Medical Expands Series E Round to Over $135 Million
Visby Medical announced today that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration for its Respiratory Health point of care test.